Rubicon Research acquires manufacturing facility in New Jersey, US

Rubicon Research Ltd. | Miscellaneous | Miscellaneous | BSE: 544578 | NSE: RUBICON

22 Jul 2026 Evaluate

Rubicon Research has acquired manufacturing facility in East Brunswick, New Jersey, United States, from InvaTech Pharma Solutions, LLC (InvaTech) at an enterprise value of $2.9 million. As part of the transaction, Rubicon has taken over the facility including the lease and all equipment, records and permits associated with the site on July 21, 2026. This acquisition gives the company a US manufacturing footprint that is about the same size as its facility at Satara and does not include any product approvals or filings. This site will focus on the company’s specialty and high value products as well as demand from US government departments. It expects to commence manufacturing its products at the site in calendar year 2027 after completing implementation of its quality management systems.

The company’s wholly owned subsidiary -- AdvaGen Holdings (AdvaGen) emerged the successful bidder in a court-supervised competitive bid process under Section 363 of the U.S. Bankruptcy Code. AdvaGen has also entered into a long-term lease on the site.

This operational facility manufactures oral solid and oral liquid formulations and has been USFDA inspected for over a decade with 3 successful inspections. The USFDA carried out an unannounced inspection of this facility in May 2026. The inspection resulted in a Form 483 issuance with 6 observations that were largely procedural in nature and unrelated to data integrity. Invatech has responded to the Form 483 within the prescribed time and has completed the corrective actions expected by the USFDA, based on which it expects the inspection to be successfully concluded in a timely manner.

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.

Rubicon Research Share Price

1464.90 -51.35 (-3.39%)

22-Jul-2026 16:59 View Price Chart

Peers

Company Name	CMP
Wework India Mgmnt.	714.80
Rubicon Research	1464.90
Aegis Vopak Terminal	295.75
Mallcom (India)	1000.00
Inducto Steel	50.87
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.